TY - JOUR
T1 - The role of p53 in the alternation of vascular functions
AU - Chan, Gabriel Hoi Huen
AU - Chan, Enoch
AU - Kwok, Carsten Tsun Ka
AU - Leung, George Pak Heng
AU - Lee, Simon Ming Yuen
AU - Seto, Sai Wang
N1 - Funding Information:
S-WS is supported by The Hong Kong Polytechnic University—General Research Fund (Project No. P0036597) and Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University (Project No. P0041138).
Publisher Copyright:
Copyright © 2022 Chan, Chan, Kwok, Leung, Lee and Seto.
PY - 2022/9/6
Y1 - 2022/9/6
N2 - Ageing is a risk factor for many degenerative diseases. Cardiovascular diseases (CVDs) are usually big burdens for elderly, caregivers and the health system. During the aging process, normal functions of vascular cells and tissue progressively lost and eventually develop vascular diseases. Endothelial dysfunction, reduced bioavailability of endothelium-derived nitric oxide are usual phenomena observed in patients with cardiovascular diseases. Myriad of studies have been done to investigate to delay the vascular dysfunction or improve the vascular function to prolong the aging process. Tumor suppressor gene p53, also a transcription factor, act as a gatekeeper to regulate a number of genes to maintain normal cell function including but not limited to cell proliferation, cell apoptosis. p53 also crosstalk with other key transcription factors like hypoxia-inducible factor 1 alpha that contribute to the progression of cardiovascular diseases. Therefore, in recent three decades, p53 has drawn scientists’ attention on its effects in vascular function. Though the role of tumor suppressor gene p53 is still not clear in vascular function, it is found to play regulatory roles and may involve in vascular remodeling, atherosclerosis or pulmonary hypertension. p53 may have a divergent role in endothelial and vascular muscle cells in those conditions. In this review, we describe the different effects of p53 in cardiovascular physiology. Further studies on the effects of endothelial cell-specific p53 deficiency on atherosclerotic plaque formation in common animal models are required before the therapeutic potential can be realized.
AB - Ageing is a risk factor for many degenerative diseases. Cardiovascular diseases (CVDs) are usually big burdens for elderly, caregivers and the health system. During the aging process, normal functions of vascular cells and tissue progressively lost and eventually develop vascular diseases. Endothelial dysfunction, reduced bioavailability of endothelium-derived nitric oxide are usual phenomena observed in patients with cardiovascular diseases. Myriad of studies have been done to investigate to delay the vascular dysfunction or improve the vascular function to prolong the aging process. Tumor suppressor gene p53, also a transcription factor, act as a gatekeeper to regulate a number of genes to maintain normal cell function including but not limited to cell proliferation, cell apoptosis. p53 also crosstalk with other key transcription factors like hypoxia-inducible factor 1 alpha that contribute to the progression of cardiovascular diseases. Therefore, in recent three decades, p53 has drawn scientists’ attention on its effects in vascular function. Though the role of tumor suppressor gene p53 is still not clear in vascular function, it is found to play regulatory roles and may involve in vascular remodeling, atherosclerosis or pulmonary hypertension. p53 may have a divergent role in endothelial and vascular muscle cells in those conditions. In this review, we describe the different effects of p53 in cardiovascular physiology. Further studies on the effects of endothelial cell-specific p53 deficiency on atherosclerotic plaque formation in common animal models are required before the therapeutic potential can be realized.
KW - atherosclerosis
KW - endothelial dysfunction
KW - p53
KW - vascular smooth muscle cell
KW - vascular smooth muscle migration
KW - vascular smooth muscle proliferation
UR - http://www.scopus.com/inward/record.url?scp=85138436466&partnerID=8YFLogxK
U2 - 10.3389/fphar.2022.981152
DO - 10.3389/fphar.2022.981152
M3 - Review article
AN - SCOPUS:85138436466
SN - 1663-9812
VL - 13
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 981152
ER -